

Edgar Filing: CYTODYN INC - Form 10QSB

CYTODYN INC
Form 10QSB
April 14, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended: February 29, 2004

Commission File Number 000-49908

CYTODYN, INC.

(Exact name of registrant as specified in its charter)

COLORADO

75-3056237

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

200 W. DeVargas Street, Suite 1, Santa Fe, New Mexico

87501

(Address of principal executive offices)

(Zip code)

(505) 988-5520

(Registrant's telephone number, including area code)

Indicate by check whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Common stock, no par value

8,019,307

Class

Number of shares outstanding at April 9, 2004

This document is comprised of 12 pages.

INDEX

Page

Edgar Filing: CYTODYN INC - Form 10QSB

PART 1 - FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed balance sheet, February 29, 2004 (unaudited).....	3
Condensed statements of operations, three and nine months ended February 29, 2004 (unaudited) and 2003 (unaudited), and May 2, 2002 (inception) through February 29, 2004 (unaudited).....	4
Condensed statements of cash flows, nine months ended February 29, 2004 (unaudited) and 2003 (unaudited) and May 2, 2002 (inception) through February 29, 2004 (unaudited).....	5
Notes to condensed financial statements (unaudited).....	6
Item 2. Plan of Operation.....	9
Item 3. Controls and Procedures.....	9

PART 2 - OTHER INFORMATION

Item 1. Legal Information.....	10
Item 2. Changes in Securities.....	10
Item 3. Defaults Upon Senior Securities.....	10
Item 4. Submission of Matters to a Vote of Security Holders.....	10
Item 5. Other Information.....	10
Item 6. Exhibits and Reports on Form 8-K.....	10
Signatures.....	11

Part 1. Item 1. Financial Information

CYTODYN, INC.
(Formerly Rexray Corporation)
(A Development Stage Company)
Condensed Balance Sheet
(Unaudited)

February 29, 2004

Assets

Cash	\$ 174,613
Equipment, net	1,650
Deposit	495

	\$ 176,758
	=====

Liabilities and Shareholders' Equity

Liabilities:

Edgar Filing: CYTODYN INC - Form 10QSB

Accounts payable and accrued liabilities	\$	93,881
Indebtedness to related parties (Note 3)		71,694

Total liabilities		165,575

Commitment (Note 7)		--
Shareholders' equity (Note 5):		
Preferred stock		--
Common stock		210,722
Additional paid-in capital		8,415
Deficit accumulated during development stage		(207,954)

Total shareholders' equity		11,183

	\$	176,758
		=====

See accompanying notes to condensed financial statements

3

CYTODYN, INC.
(Formerly Rexray Corporation)
(A Development Stage Company)
Condensed Statements of Operations
(Unaudited)

	Three Months Ended February 29,		Nine Month Februar
	2004	2003	2004
	-----	-----	-----
Operating expenses:			
Stock-based compensation:			
Incorporation and organization services\$..	--	\$ --	\$ --
Compensation	10,703	--	55,703
Contributed services, related party (Note 3)	--	240	--
Contributed rent, related party (Note 3)	--	300	500
Rent, related party (Note 3)	--	--	--
Rent, other	1,485	--	2,240
Professional fees	101,631	1,025	114,127
Interest income	(52)	--	(55)
Interest expense	296	--	441
Other	15,177	19	16,359
	-----	-----	-----

Edgar Filing: CYTODYN INC - Form 10QSB

Total operating expenses	129,240	1,584	189,315
	-----	-----	-----
Loss before income taxes	(129,240)	(1,584)	(189,315)
Income tax provision (Note 6)	--	--	--
	-----	-----	-----
Net loss	\$ (129,240)	\$ (1,584)	\$ (189,315)
	=====	=====	=====
Basic and diluted loss per share	\$ (0.02)	\$ (0.00)	\$ (0.05)
	=====	=====	=====
Basic and diluted weighted average common shares outstanding	* 6,674,862	* 590,000	* 3,909,985
	=====	=====	=====

* Restated for 1:2 reverse split of common stock (see Note 2)

See accompanying notes to condensed financial statements

4

CYTODYN, INC.
(Formerly Rexray Corporation)
(A Development Stage Company)
Condensed Statements of Cash Flows
(Unaudited)

	Nine Months Ended February 29,		May 2, 2002 (Inception Through February 2 2004
	2004	2003	
	-----	-----	-----
Net cash used in operating activities	\$ (191,741)	\$ (2,720)	\$ (196,91
	-----	-----	-----
Cash flows from investing activities:			
Equipment purchases	(1,722)	--	(1,72
	-----	-----	-----
Net cash used in investing activities	(1,722)	--	(1,72

Edgar Filing: CYTODYN INC - Form 10QSB

Cash flows from financing activities:			
Expenses paid by an officer on behalf of the Company (Note 3)	2,500	900	4,14
Proceeds from related party advance (Note 3)	10,000	--	10,00
Proceeds from the sale of common stock (Note 5) ..	405,000	200	408,60
Payment of offering costs	(49,500)	--	(49,50)
Net cash provided by financing activities	368,000	1,100	373,24
Net change in cash	174,537	(1,620)	174,61
Cash, beginning of period	76	1,714	--
Cash, end of period	\$ 174,613	\$ 94	\$ 174,61
Supplemental disclosure of cash flow information:			
Income taxes	\$ --	\$ --	\$ --
Interest	\$ --	\$ --	\$ --
Non-cash investing and financing transactions:			
Net liabilities acquired in exchange for common stock in CytoDyn agreement (Note 2)	\$ (161,578)	\$ --	\$ (161,57)
Common stock issued as payment of accounts payable (Note 5)	\$ 5,000	\$ --	\$ 5,00

See accompanying notes to condensed financial statements

5

CYTODYN, INC.
(Formerly Rexray Corporation)
(A Development Stage Company)

Notes to Condensed Financial Statements
(Unaudited)

Note 1: Basis of Presentation

The condensed financial statements presented herein have been prepared by the Company in accordance with the instructions for Form 10-QSB and the accounting policies in its Form 10-KSB filed for the year ended May 31, 2003 and should be read in conjunction with the notes thereto.

In the opinion of management, the accompanying condensed financial statements contain all adjustments (consisting only of normal recurring adjustments) which are necessary to provide a fair presentation of operating results for the

Edgar Filing: CYTODYN INC - Form 10QSB

interim periods presented. The results of operations presented for the three and nine months ended February 29, 2004 are not necessarily indicative of the results to be expected for the year.

The Company is in the development stage in accordance with Statements of Financial Accounting Standards (SFAS) No. 7 "Accounting and Reporting by Development Stage Enterprises". On October 28, 2003, CytoDyn, Inc. (the "Company" or the "Registrant", formerly known as Rexray Corporation) closed an Acquisition Agreement with CytoDyn of New Mexico, Inc. ("CytoDyn NM") (see Note 2).

Financial data presented herein are unaudited.

Note 2: Acquisition Agreement

Terms

On October 28, 2003, the Registrant closed an Acquisition Agreement with CytoDyn NM. Under the terms of the Acquisition Agreement, CytoDyn NM:

- o Assigned the patent license agreement between CytoDyn NM and Allen D. Allen covering United States patent numbers 5424066, 5651970, and 6534057, and related foreign patents and patents pending, for a method of treating HIV disease with the use of monoclonal antibodies;
- o Assigned its trademarks, CytoDyn and Cytolin, and related trademark symbol; and
- o Paid \$10,000 in cash

CytoDyn of NM retained all other assets, including its shares of Amerimmune Pharmaceuticals, Inc.

In consideration for the above, the Registrant:

- o Effected a one-for-two reverse split of its common stock;
- o Issued 5,362,640 shares of its common stock to CytoDyn NM;
- o Amended its Articles of Incorporation to change its name to CytoDyn, Inc.; and
- o Accepted \$161,578 in liabilities related to the assigned assets

Other Compensation

The Registrant issued a promissory note in the amount of \$30,000 to its former president, James B. Wiegand, for payment of services rendered in connection with the acquisition. This note was paid during the fiscal quarter ended February 29, 2004.

6

Change in Control

Following the closing of the Acquisition Agreement, CytoDyn NM held 5,362,640, or 85.8 percent, of the Registrant's 6,252,640 common shares issued and outstanding, which resulted in a change in control of the Registrant.

Accounting and Valuation

The same party (CytoDyn NM) controlled the assigned assets and liabilities before and after the closing of the Acquisition Agreement. Therefore, the

Edgar Filing: CYTODYN INC - Form 10QSB

assigned assets and liabilities were recorded on the books of the Registrant based on CytoDyn NM's book value on the closing date. On October 28, 2003, the book value of the assigned assets and liabilities was \$-0-, and \$161,578, respectively. As a result, the Registrant credited liability accounts for \$161,578 with an offset against "additional paid-in capital".

Note 3: Related Party Transactions

On December 26, 2003, an officer advanced the Company \$50,000 for working capital. The advance did not bear interest and was due on demand. The Company repaid the advance in February 2004.

As part of the above Acquisition Agreement, the Company acquired \$161,578 in liabilities of which \$61,694 is owed to officers and directors. The liabilities were incurred as a result of maintaining the patents and other intangible assets. The \$61,694 is included in the accompanying condensed financial statements as "Indebtedness to related parties".

During October 2003, an officer advanced the Company \$10,000. The advance does not bear interest and is due on demand. The advance is included in the accompanying condensed financial statements as "Indebtedness to related parties".

During the six months ended November, 30, 2003, an officer contributed \$2,500 to the Company for working capital. The working capital contributions are included in the accompanying financial statements as "Additional paid-in capital".

During the period from October 2002 through October 27, 2003, Amery Coast Corporation ("ACC"), at that time an affiliate under common control contributed office space to the Company. The office space was valued at \$100 per month based on the market rate in the local area and is included in the accompanying financial statements as "Contributed rent, related party" expense with a corresponding credit to "Additional paid-in capital".

The Company paid rent to ACC from May 2002 through September 2002. The office space was valued at \$100 per month based on the market rate in the local area and is included in the accompanying financial statements as "Rent, related party".

Note 4: Note Payable

Effective October 28, 2003, the Company issued a \$30,000 promissory note to its former president as payment for services related to the CytoDyn NM Acquisition Agreement. The note carried a five percent interest rate and was due on January 27, 2004. The Company repaid the \$30,000 note, and \$442 in accrued interest, in February 2004.

7

Note 5: Shareholders' Deficit

During the fiscal quarter ended February 29, 2004, the Company sold 1,250,000 shares of its common stock at \$.30 per share for net proceeds totaling \$325,500, after deducting commissions of \$37,500 and offering costs of \$12,000. The Company relied upon exemptions from registration believed by it to be available under federal and state securities laws in connection with the sales.

During February 2004, the Company issued 16,667 shares of its common stock as payment for a \$5,000 officer liability (\$.30 per share).

Edgar Filing: CYTODYN INC - Form 10QSB

During September 2003, the Company sold 600,000 shares of its common stock for gross proceeds totaling \$30,000 (\$.05 per share). The Company relied upon exemptions from registration believed by it to be available under federal and state securities laws in connection with the sales. The shares were sold through the Company's former officer and director.

Following is a schedule of changes in shareholders' deficit for the nine months ended February 29, 2004:

	Common stock		Additional Paid-In Capital	Retained Deficit	T
	Shares	Amount			
Balance, June 1, 2003	1,180,000	\$ 11,800	\$ 5,415	\$ (18,639)	\$
Capital contributed by an officer ..	--	--	2,500	--	
September 2003, sale of common stock, \$.05/share	600,000	30,000	--	--	
October 2003, reverse split of common stock	(890,000)	--	--	--	
October 2003, common stock issued in CytoDyn NM Acquisition Agreement .	5,362,640	(161,578)	--	--	(
February 2004, sale of common, less offering costs of \$49,500 at \$.30/share	1,250,000	325,500	--	--	
February 2004, common stock issued as payment for officer liability .	16,667	5,000	--	--	
Office space contributed by an affiliate	--	--	500	--	
Net loss for the nine months ended February 29, 2004	--	--	--	(189,315)	(
Balance, February 29, 2004	7,519,307	\$ 210,722	\$ 8,415	\$ (207,954)	\$

Note 6: Income taxes

The Company records its income taxes in accordance with SFAS No. 109, "Accounting for Income Taxes". The Company incurred net operating losses for all periods presented resulting in a deferred tax asset, which was fully allowed for; therefore, the net benefit and expense resulted in \$-0- income taxes.

Note 7: Commitment

The Company entered into a noncancellable operating lease for office space that commenced November 14, 2003 and expires November 30, 2004. Payments required under the operating lease are \$495 per month.

Part I. Item 2. Plan of operation

PLAN OF OPERATION

Edgar Filing: CYTODYN INC - Form 10QSB

CytoDyn, Inc. is a development-stage company that plans to develop therapeutic agents for use against disease associated with HIV using licensed patented technology. We intend to develop, and obtain FDA approval for the use of, monoclonal antibodies to treat patients with HIV by protecting the cells of the body's immune system that are otherwise killed by the disease. No revenues have been derived from our licensed technology, but Phase I clinical trials have been conducted with promising outcomes. We plan to continue clinical trials during the next 12 months and thereafter if necessary. We plan to outsource the manufacturing of the antibodies, as we do not have, and do not plan to have, our own manufacturing facilities.

We plan to raise approximately \$540,000 through the sale through a private placement, of our common stock in early 2004. We collected \$375,000 as of February 29, 2004. We expect that these funds will satisfy our cash requirements through December 31, 2004, when additional financing will once again be required, the amount of which will depend on the status of our operations. We also plan to register our common shares on the OTC Bulletin Board within the first six months of 2004.

As of February 29, 2004, we had 2 full time employees, both officers of the Company. We may retain additional employees during the latter half of 2004 if our second round of financing is successful.

We have no plans for significant purchases of plant or equipment.

Special note regarding forward-looking statements

We make statements in this report and the documents incorporated by reference that are considered forward-looking statements under the federal securities laws. You may find many of these statements by looking for words like "intends," "expects," "projects," "believes," "anticipates" or similar expressions in this report. We consider all statements regarding anticipated or future matters, including the following, to be forward-looking statements:

- o statements about future events and our future financial performance;
- o financing plans and expectations of internally-generated cash flows;
- o obtaining and maintaining regulatory approval and changes in regulations, including regulatory approvals for Cytolin;
- o benefits from new technology;
- o commercial acceptance of new products;
- o business strategy;
- o plans and objectives of management for future operations;
- o competitive position;
- o competitive pressures;
- o changing economic conditions; and
- o our ability to manufacture and distribute our products.

9

These statements are not guarantees of our future performance. They are based upon our assumptions and assessments only on the date we made them and in light of our experience and our perception of historical trends, current conditions, expected future developments, and other factors we believe to be appropriate. Our assumptions and assessments include the volume and product mix of sales, estimates of costs and inventory and receivable levels based on preliminary information, and others. Risks, uncertainties, and other important factors could cause actual performance or achievements to be materially different from those we may project. The factors that could cause actual results to differ materially from those in the forward-looking statements include:

Edgar Filing: CYTODYN INC - Form 10QSB

- o industry conditions and competition;
- o reforms in the health care industry or limitations imposed on third party or Medicare reimbursement of health care costs;
- o changes in the Food and Drug Administration approval requirements and process;
- o the rate of market acceptance of our products, particularly Cytolin;
- o operational risks and insurance;
- o risks associated with operating in foreign jurisdictions;
- o product liabilities that may arise in the future which are not covered by insurance or indemnity;
- o the impact of current and future laws and government regulations affecting the pharmaceutical industry and our operation in particular; and
- o the ability to retain key personnel.

Part I. Item 3. Controls and Procedures

Quarterly Controls Evaluation and Related CEO and CFO Certifications

As of the end of the period covered by this Quarterly Report on Form 10-QSB, we evaluated the effectiveness of the design and operation of "disclosure controls and procedures" (Disclosure Controls). The controls evaluation was done under the supervision and with the participation of management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO).

Attached as Exhibits to this Quarterly Report on Form 10-QSB are certifications of the CEO (Exhibit 31.1) and the CFO (Exhibit 31.2), which are required in accordance with Rule 13a-14 of the Securities Exchange Act of 1934 (the Exchange Act). This Controls and Procedures section includes the information concerning the controls evaluation referred to in the certifications and it should be read in conjunction with the certifications for a more complete understanding of the topics presented.

10

Disclosure Controls and Internal Controls

Disclosure Controls are procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission's rules and forms. Disclosure Controls are also designed to ensure that the information is accumulated and communicated to our management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Internal control over financial reporting (Internal Controls) are procedures which are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that: (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of CYTODYN; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of CYTODYN are being made only in accordance with authorizations of management and directors of CYTODYN; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the CYTODYN' assets

Edgar Filing: CYTODYN INC - Form 10QSB

that could have a material effect on the financial statements. To the extent that components of our Internal Controls are included in our Disclosure Controls, they are included in the scope of our quarterly controls evaluation.

Limitations on the Effectiveness of Controls

Our management, including the CEO and CFO, does not expect that our Disclosure Controls will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

11

Conclusions

Based on our controls evaluation (with the participation of our CEO and CFO), as of the end of the period covered by this report, our CEO and CFO have concluded that, subject to the limitations noted above, our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the "Exchange Act")) are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

There was no change in our internal control over financial reporting during the third fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part 2. Other Information

Item 1 - Legal Information.

For information on Legal Proceedings in the case styled: CytoDyn of New Mexico, Inc. on behalf of itself and for the benefit of all persons disabled by AIDS/HIV; Terri Hess, on behalf of himself and for the benefit of all persons disabled By AIDS/HIV, vs. Amerimmune Pharmaceuticals, Inc.; Rex Lewis; Pamela M. Kapustay; Kimberly L. Cerrone; O.B. Parish; Michael A. Davis; and Does 1 through 10 inclusive, Superior Court of California, in the County of Los Angeles,

Edgar Filing: CYTODYN INC - Form 10QSB

Central District, Case No. BC290154, filed on February 11, 2003, see the Registrant's Form 10QSB for the quarter ended November 30, 2003.

Item 2 - Changes in Securities.

During the fiscal quarter ended February 29 2004, the Company sold, in a private placement, 1,250,000 shares of its common stock at \$.30 per share, for net proceeds totaling \$325,500, after deducting commissions of \$37,500 in commissions and other offering costs of \$12,000. The Company relied upon exemptions from registration under Regulation D, promulgated under the Securities Act of 1933. All purchasers were accredited investors as that term is defined in Regulation D, and all gave representations that they purchased with an investment intent and with no intention to distribute their shares. All share certificates bear restrictive legends.

During February 2004, the Company issued 16,667 shares of its common stock as payment for a \$5,000 liability to officer Brian McMahon, V.P. (\$.30 per share) under Section 4(6) of the Securities Act of 1933. Mr. McMahon was an accredited investor and took the shares with investment intent and not for distribution. The share certificate bears a restrictive legend.

12

Item 6 - Exhibits and Reports on Form 8-K.

(a) Exhibits:

- 3.i (1) Articles of Incorporation
- 3.i.2 (1) Amendment to Articles of Incorporation
- 3.ii (1) Bylaws
- 31.1: Section 302 Certification of Allen D. Allen
- 31.2: Section 302 Certification of Corinne E. Allen
- 32.1: Section 906 Certification of Allen D. Allen
- 32.2: Section 906 Certification of Corinne E. Allen

(1) See Exhibit Index

(b) Reports on Form 8-K:

Amendment No 1 to Form 8-K filed on January 12, 2004 to amend and restate Item 1. of the original Form 8-K filed on November 12, 2003 which reported under Item 1, the change of control of the Registrant, formerly Rexray Corporation and to file exhibits to the Form 8-K.

SIGNATURES

In accordance with the requirements of the Securities and Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CYTODYN, INC.
(Formerly Rexray Corporation)
(Registrant)

Edgar Filing: CYTODYN INC - Form 10QSB

DATE: April 14, 2004

BY: /s/ Allen D. Allen

Allen D. Allen
President and Chief Executive Officer

DATE: April 14, 2004

BY: /s/ Corinne E. Allen

Corinne E. Allen
Chief Financial Officer

13

Index to Exhibits

Exhibit No.	Exhibit Description	Incorporated by Reference			Filed
		Form	File No	Exhibit No.	Filing Date
3.i	Articles of Incorporation	10SB	000-49908	3.1	7/11/2002
3.i.2	Amendment to Articles of Incorporation	8K	000-49908	3.i.2	11/12/2003
3.ii	Bylaws	10SB	000-49908	3.2	7/11/200
31.1:	Section 302 Certification of Allen D. Allen				
31.2:	Section 302 Certification of Corinne E. Allen				
32.1:	Section 906 Certification of Allen D. Allen				
32.2	Section 906 Certification of Corinne E. Allen				

14